摘要
载脂蛋白 ε 4 等位基因是晚发性阿尔茨海默病 (AD) 的主要危险因素。已经证明AD的不同状态取决于载脂蛋白ε4等位基因的不同表型特征。载脂蛋白ε4 非携带者的遗传病因仍然未被发现。因此,通过结合基因组关联分析和定量相关分析,我们研究了与阿尔茨海默病神经影像倡议组织(ADNI)队列的非西班牙裔白人参与者的独立的载脂蛋白ε 4 的 AD 遗传成份。五个最易感单核苷酸多态性 (SNPs)在三个基因座 ZNF827、 KDM2B 和 NANP被最初发现在载脂蛋白 E 4 非携带者和对这些 SNPs 的四个证实轻度认知功能障碍的患者中。这些 SNP 位点和一个已知的、重要的SNPs位于三个单倍型的区域。这些单倍型定量相关分析表明在 ZNF827 中的单倍型与脑脊液 Aβ42 水平和与脑脊液 p tau181p 和 p-tau181p/Aβ42 比值在 KDM2B 中的单倍型相关联。NANP 和 NINL 之间的单倍型整体联系着脑萎缩。此外,这些 SNP对AD发病率有额外的影响,并且证实了其表现出与载脂蛋白 E 4 状态的相互作用。因此,我们认为这些在载脂蛋白 ε 4 非携带者中与AD相关的新位点。这项研究表明AD的非携带载脂蛋白 E 4 等位基因的不同的遗传易感性,并提供新的AD 分子机制的见解。
关键词: 阿尔茨海默病;载脂蛋白 E ε 4;脑萎缩;诊断生物学标记;单体;单核苷酸多态性
Current Alzheimer Research
Title:Identification of Novel Quantitative Traits-Associated Susceptibility Loci for APOE ε 4 Non-Carriers of Alzheimer’s Disease
Volume: 12 Issue: 3
Author(s): Shan Jiang, Wanling Yang, Yu Qiu, Hong-Zhuan Chen and for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Affiliation:
关键词: 阿尔茨海默病;载脂蛋白 E ε 4;脑萎缩;诊断生物学标记;单体;单核苷酸多态性
摘要: APOE ε4 allele is a major risk factor in Late-Onset Alzheimer’s Disease (AD). Distinct phenotypes that depend on the APOE ε4 status have been demonstrated. The genetic etiology of APOE ε4 non-carriers is still elusive. Thus we investigated the genetic components of AD that is independent of APOE ε4 by combining genome association analysis with quantitative trait analyses in non-Hispanic Caucasian participants in the Alzheimer’ s Disease Neuroimaging Initiative (ADNI) cohort. Five top susceptible single nucleotide polymorphisms (SNPs) in three loci in ZNF827, KDM2B and NANP were initially identified in APOE ε4 non-carriers and four of these SNPs were confirmed in mild cognitive impairment. These SNPs and one nominally significant SNP are located in three haplotype blocks. Quantitative trait analyses of these haplotype blocks demonstrated that the haplotype block in ZNF827 was associated with CSF Aβ42 level, and the haplotype block in KDM2B with CSF p-tau181p and p-tau181p/Aβ42 ratio. The haplotype block between NANP and NINL was associated with brain atrophy. Moreover, these SNPs took additive effects on AD incidence and demonstrated the interaction with APOE ε4 status. Therefore, we conclude that these novel loci are associated with AD in APOE ε4 non-carriers. This study indicates the distinct genetic risk genes for AD non-carrying APOE ε4 and provides new insight into the molecular mechanisms of AD.
Export Options
About this article
Cite this article as:
Shan Jiang, Wanling Yang, Yu Qiu, Hong-Zhuan Chen and for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , Identification of Novel Quantitative Traits-Associated Susceptibility Loci for APOE ε 4 Non-Carriers of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302160145
DOI https://dx.doi.org/10.2174/1567205012666150302160145 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Conference Report: 8<sup>th</sup> Clinical Trials on Alzheimer Disease (CTAD), Barcelona, Spain November 5-7, 2015
CNS & Neurological Disorders - Drug Targets Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Development of Bivalent Acetylcholinesterase Inhibitors as Potential Therapeutic Drugs for Alzheimers Disease
Current Pharmaceutical Design Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Pleasure as an Overlooked Target of Substance Use Disorder Research and Treatment
Current Drug Abuse Reviews Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry Effect of Brain-Derived Neurotrophic Factor (BDNF) Gene Variants on the Therapeutic Response and the Risk for Mood Disorders
Current Pharmacogenomics and Personalized Medicine EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Current Alzheimer Research Impaired Functional Connectivity of the Thalamus in Alzheimer’ s Disease and Mild Cognitive Impairment: A Resting-State fMRI Study
Current Alzheimer Research Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Structure and Ligand Based Rational Drug Design for Bace-1 Inhibitors
Current Bioactive Compounds Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Natural Phytochemicals and Their Therapeutic Role in Management of Several Diseases: A Review
Current Traditional Medicine Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology rs3851179G>A in PICALM is Protective Against Alzheimer’s Disease in Five Different Countries Surrounding the Mediterranean
Current Aging Science